Follow-The-Filings

Security

Corbus Pharmaceuticals Hldgs · COM NEW

Equity holders as of 2026 Q1 (each manager’s latest book)

10 owners max 0.0% (Renaissance Technologies LLC)

owners 10
max % 0.0%
tracked value $21M
qoq A 3 R 5

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Renaissance Technologies LLC 2026 Q1 0.0% Reduce 0.00 pp 346,998 $3M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 859,407 $7M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Reduce 0.00 pp 727,060 $7M hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Add 0.00 pp 146,596 $1M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Add 0.00 pp 107,800 $1M hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Reduce 0.00 pp 65,201 $612 hist
Steve Cohen - Point72 Asset Management, L.P. 2026 Q1 0.0% Reduce 0.00 pp 51,296 $482 hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% Reduce 0.00 pp 26,474 $249 hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 12,480 $102 hist
Ancora Advisors LLC 2026 Q1 0.0% 64 $1 hist

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue
Gross profit
Gross margin
Net income -$44.6M -$40.21M -$78.54M
Net margin

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $23.55M $152.98M $166.95M
Total non-current assets * $4.73M $2.9M $1.24M
Total assets $28.27M $155.88M $168.2M
Total current liabilities $31.89M $11.82M $20.69M
Total non-current liabilities * $3.28M $1.63M $0.00
Total equity -$6.9M $142.43M $147.5M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$36.1M -$41.79M -$64.49M
Cash from investing $35.64M -$121.31M -$1.64M
Cash from financing -$2.82M $166.58M $77.43M
Net change in cash -$3.28M $3.47M $11.29M

ownership over time

filing count by report period · click a bar for that quarter’s holders